Connection

Gary Gilkeson to Nitric Oxide

This is a "connection" page, showing publications Gary Gilkeson has written about Nitric Oxide.
Connection Strength

1.614
  1. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol. 2006 Dec; 121(3):243-50.
    View in: PubMed
    Score: 0.232
  2. Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide. J Pharmacol Exp Ther. 2005 Jan; 312(1):69-76.
    View in: PubMed
    Score: 0.204
  3. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. J Investig Med. 2004 Jan; 52(1):62-71.
    View in: PubMed
    Score: 0.194
  4. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol. 2000 Feb 01; 164(3):1498-504.
    View in: PubMed
    Score: 0.148
  5. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians. 1999 Nov-Dec; 111(6):611-21.
    View in: PubMed
    Score: 0.145
  6. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol. 1999 Feb; 26(2):318-24.
    View in: PubMed
    Score: 0.138
  7. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol. 1997 Apr; 83(1):86-92.
    View in: PubMed
    Score: 0.122
  8. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med. 1994 Feb 01; 179(2):651-60.
    View in: PubMed
    Score: 0.098
  9. Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PLoS One. 2013; 8(5):e64650.
    View in: PubMed
    Score: 0.093
  10. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. Am J Med Sci. 2011 Feb; 341(2):101-5.
    View in: PubMed
    Score: 0.079
  11. Inflammatory modulation of PPAR gamma expression and activity. Clin Immunol. 2006 Feb-Mar; 118(2-3):276-83.
    View in: PubMed
    Score: 0.055
  12. Nitrosylation of blood hemoglobin and renal nonheme proteins in autoimmune MRL-lpr/lpr mice. Free Radic Biol Med. 1998 Jan 01; 24(1):191-6.
    View in: PubMed
    Score: 0.032
  13. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J Exp Med. 1997 Aug 04; 186(3):365-73.
    View in: PubMed
    Score: 0.031
  14. A novel PPAR response element in the murine iNOS promoter. Mol Immunol. 2005 Jul; 42(11):1303-10.
    View in: PubMed
    Score: 0.013
  15. Peroxisome proliferator-activated receptor-gamma agonists modulate macrophage activation by gram-negative and gram-positive bacterial stimuli. Shock. 2003 Jul; 20(1):56-62.
    View in: PubMed
    Score: 0.012
  16. Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation. J Leukoc Biol. 2001 Apr; 69(4):631-8.
    View in: PubMed
    Score: 0.010
  17. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. J Exp Med. 1996 Sep 01; 184(3):1173-8.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.